Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ...
A one-minute jab is being rolled out across the NHS to treat 14 types of cancer. Tens of thousands of patients will be able to receive immunotherapy in a fraction of the normal ti ...
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. The indications or uses for this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results